A Study of Olaratumab in Japanese Participants With Advanced Cancer

NCT02377752 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasm

Interventions

BIOLOGICAL: Olaratumab
DRUG: Doxorubicin

Sponsor

Eli Lilly and Company